Compare Novavax Inc (NVAX) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs United States Natural Gas Fund — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while United States Natural Gas Fund trades at $11.04 (market cap $517.27M). The key difference: Novavax Inc is far larger — about 3.5× United States Natural Gas Fund's market cap, and Novavax Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and United States Natural Gas Fund for 22 Days on average.
| NVAX | UNG | |
|---|---|---|
Market Cap | $1.82B | $517.27M |
Volume | 6,198,505 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $12.56 | $16.90 |
52-Week Low | $6.22 | $9.63 |
Typical Hold Time | 59 Days | 22 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
UNG trades at $11.10, up 0.63% with a bullish technical signal from moving averages. The fund shows strong profitability with $65.15M net income for 2024, though revenue remains at $0.00. Recent news highlights natural gas market volatility with record production levels and geopolitical tensions affecting energy prices. The fund maintains a solid balance sheet with $594.68M in current assets and minimal liabilities.
Investment outlook remains cautiously optimistic given bullish technical indicators and strong profitability metrics. Key risks include natural gas price volatility and geopolitical factors affecting energy markets. The absence of traditional valuation metrics requires careful monitoring of underlying commodity trends for informed positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
